(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 335K | -53% |
Gross Profit | 87.1K | -86% |
Cost Of Revenue | 248K | - |
Operating Income | -3.5MM | +11% |
Operating Expenses | 3.6MM | - |
Net Income | -3.5MM | +10% |
G&A | 1.8MM | -30% |
Marketing | 375.5K | +12% |
Amortization | 6.9K | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Predictive Oncology Inc. (NASDAQ:POAI) Q4 2023 Earnings Call Transcript April 1, 2024 Predictive Oncology Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings and welcome to the Predictive Oncology Fourth Quarter 2023 Earnings Call. At this time all participants […]
Predictive Oncology ( NASDAQ:POAI ) Full Year 2023 Results Key Financial Results Revenue: US$1.78m (up 18% from FY...
Company to host investor call and webcast on Monday, April 1st, at 8:30am EDTPITTSBURGH, March 28, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the year ended December 31, 2023,
PITTSBURGH, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond F. Vennare, Chief Executive Officer, will participate in three upcoming investor conferences. Please see below for additional details about the events and how to request a one-on-one meeting with management. BIO CEO & Investor ConferenceLocation: New York, NYFormat: Company presentationPresentation Date: Tuesday, February 27, 2024
PITTSBURGH, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond F. Vennare, Chief Executive Officer, will present at the upcoming Biotech Showcase, in San Francisco, CA, on January 9, 2024, at 4:00 p.m. PT. Company management will also participate in the 13th Annual LifeSci Partners Corporate Access Event and BIO Partnering @ JPM Week 2024. Please see below for additional details about the eve
Company to host investor call and webcast today, November 14th, at 8:30am EDTPITTSBURGH, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three and nine months ended Sep
PITTSBURGH, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that it has completed a multi-year study with UPMC Magee-Womens Hospital. The objective of the study was to evaluate the use of AI to build multi-omic machine learning (ML) models and test if these models can learn associations between the datasets and ovarian cancer patient short- and long-term survival. “This study incorporated one of the la
Management to host conference call and webcast at 8:30am EDTEAGAN, Minn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that
Company to host investor call and webcast today, August 10th, at 5:30pm EDTPITTSBURGH, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three and six months ended June 30
Management to host conference call and webcast at 5:30pm EDTEAGAN, Minn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that